Preclinical evaluation of 188Re-HYNIC-PSMA as a novel therapeutic agent

2022 ◽  
Author(s):  
Maliheh Hadisi ◽  
Naser Vosoughi ◽  
Hassan Yousefnia ◽  
Ali Bahrami-Samani ◽  
Samaneh Zolghadri ◽  
...  
Keyword(s):  
Therapeutic Agent ◽  
Preclinical Evaluation ◽  
Novel Therapeutic

Cerium oxide nanoparticles acts as a novel therapeutic agent for ulcerative colitis through anti-oxidative mechanism

Life Sciences ◽  
2021 ◽  
pp. 119500
Author(s):  
Fereshteh Asgharzadeh ◽  
Alireza Hashemzadeh ◽  
Farzad Rahmani ◽  
Atieh Yaghoubi ◽  
Seyedeh Elnaz Nazari ◽  
...  
Keyword(s):  
Ulcerative Colitis ◽  
Cerium Oxide ◽  
Therapeutic Agent ◽  
Cerium Oxide Nanoparticles ◽  
Oxide Nanoparticles ◽  
Novel Therapeutic

scholarly journals Propofol Inhibits the Proliferation, Migration, and Stem-like Properties of Bladder Cancer Mainly by Suppressing the Hedgehog Pathway

2021 ◽  
Vol 30 ◽  
pp. 096368972098511
Author(s):  
Gang Li ◽  
Xu Zhang ◽  
Xiangyang Guo ◽  
Yi Li ◽  
Chong Li
Keyword(s):  
Stem Cells ◽  
Bladder Cancer ◽  
Bladder Tumor ◽  
Therapeutic Agent ◽  
Tumor Formation ◽  
The Self ◽  
Hedgehog Pathway ◽  
Self Renewal ◽  
Intravenous Anesthetic ◽  
Novel Therapeutic

Bladder cancer is one of the most common malignancies. The existence of bladder cancer stem cells (BCSCs) has been suggested to underlie bladder tumor initiation and recurrence. Propofol is a commonly used intravenous anesthetic. Here, we find that propofol can dramatically block the activation of Hedgehog pathway in BCSCs. The propofol strongly repressed the growth of cancer cells. Attenuated proliferation and enhanced apoptosis of tumor cells were observed upon propofol stimulation. Furthermore, propofol reduced the self-renewal ability of BCSCs as well as the tumor formation. In conclusion, propofol is potentially used as a novel therapeutic agent for bladder cancer by targeting self-renewal through inhibiting Hedgehog pathway.

scholarly journals Evaluating the potential of IL-27 as a novel therapeutic agent in HIV-1 infection

2013 ◽  
Vol 24 (6) ◽  
pp. 571-577 ◽  
Author(s):  
Sanjay Swaminathan ◽  
Lue Dai ◽  
H. Clifford Lane ◽  
Tomozumi Imamichi
Keyword(s):  
Therapeutic Agent ◽  
Hiv 1 ◽  
Novel Therapeutic

scholarly journals Should hydrogen therapy be included in a musculoskeletal medicine routine?

F1000Research ◽  
2016 ◽  
Vol 5 ◽  
pp. 2659 ◽  
Author(s):  
Sergej M. Ostojic
Keyword(s):  
Health Professionals ◽  
Molecular Hydrogen ◽  
Therapeutic Agent ◽  
Metabolic Diseases ◽  
Neuromuscular Disorders ◽  
Surrogate Markers ◽  
Musculoskeletal Medicine ◽  
Inflammatory Agent ◽  
Medicinal Properties ◽  
Novel Therapeutic

Molecular hydrogen (H2) has recently been recognized as a potential novel therapeutic agent in biomedicine. Initially proposed to be a possible treatment for certain types of neuromuscular disorders, cardio-metabolic diseases and cancer, H2 improved clinical end-points and surrogate markers in several clinical trials, mainly acting as an anti-inflammatory agent and powerful antioxidant. In this paper, the medicinal properties of H2 in musculoskeletal medicine are discussed with the aim to provide an updated and practical overview for health professionals working in this field.

scholarly journals Structure Based Design and Synthesis of Peptide Inhibitor of Human LOX-12: In Vitro and In Vivo Analysis of a Novel Therapeutic Agent for Breast Cancer

PLoS ONE ◽  
2012 ◽  
Vol 7 (2) ◽  
pp. e32521 ◽  
Author(s):  
Abhay kumar Singh ◽  
Ratnakar Singh ◽  
Farhat Naz ◽  
Shyam Singh Chauhan ◽  
Amit Dinda ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Therapeutic Agent ◽  
Peptide Inhibitor ◽  
Design And Synthesis ◽  
In Vivo Analysis ◽  
Novel Therapeutic
Sign in / Sign up

Export Citation Format

Share Document